Account-creators
1,040
edits
Difference between revisions of "Oligodendroglioma"
Jump to navigation
Jump to search
→Microscopic: DDx intraop
Jensflorian (talk | contribs) (→Histologic grading: IDH1 and 2) |
Jensflorian (talk | contribs) (→Microscopic: DDx intraop) |
||
| (9 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
| Image = Oligodendroglioma1_high_mag.jpg | | Image = Oligodendroglioma1_high_mag.jpg | ||
| Width = | | Width = | ||
| Caption = Oligodendroglioma. [[H&E stain]]. | | Caption = Oligodendroglioma,IDH mutant and 1p/19q codeleted. [[H&E stain]]. | ||
| Synonyms = | | Synonyms = | ||
| Micro = highly cellular lesion composed of cells resembling ''fried eggs'' (oligodendrocytes) with a round nucleus (important), distinct cell borders, +/-clear cytoplasm - useful feature (if present), acutely branched capillary sized vessels ("chicken-wire" like appearance), calcifications | | Micro = highly cellular lesion composed of cells resembling ''fried eggs'' (oligodendrocytes) with a round nucleus (important), distinct cell borders, +/-clear cytoplasm - useful feature (if present), acutely branched capillary sized vessels ("chicken-wire" like appearance), calcifications | ||
| Line 30: | Line 30: | ||
| Tx = | | Tx = | ||
}} | }} | ||
'''Oligodendroglioma''' is [[CNS tumour]] that is typically in the cerebral hemispheres. | '''Oligodendroglioma, IDH mutant and 1p/19q codeleted''' is [[CNS tumour]] that is typically in the cerebral hemispheres. Molecular analysis of IDH1/2 hotspots and LOH1p/19q testing is required for diagnosis. | ||
==General== | ==General== | ||
| Line 37: | Line 37: | ||
Prognosis by flavours (average survival):<ref name=Ref_PSNP98>{{Ref PSNP|98}}</ref> | Prognosis by flavours (average survival):<ref name=Ref_PSNP98>{{Ref PSNP|98}}</ref> | ||
*WHO grade | *WHO CNS grade 2: 10-15 years. | ||
*WHO grade | *WHO CNS grade 3: 3-5 years. | ||
Oligodendrogliomas account for approx 5% of all [[glioma]]s. | Oligodendrogliomas account for approx 5% of all [[glioma]]s. | ||
| Line 45: | Line 45: | ||
* First description of the tumor in 1926. | * First description of the tumor in 1926. | ||
The WHO | The fifth edition of WHO classification recognizes two tumor subtypes: | ||
*Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, WHO CNS Grade 2 (ICD-O: 9450/3). | |||
*Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, WHO CNS Grade 3 (ICD-O: 9451/3). | |||
The terminology anaplastic oligodendroglioma or oligoastrocytoma is depreceated. <ref>{{Cite journal | last1 = Louis | first1 = DN. | last2 = Perry | first2 = A. | last3 = Reifenberger | first3 = G. | last4 = von Deimling | first4 = A. | last5 = Figarella-Branger | first5 = D. | last6 = Cavenee | first6 = WK. | last7 = Ohgaki | first7 = H. | last8 = Wiestler | first8 = OD. | last9 = Kleihues | first9 = P. | title = The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. | journal = Acta Neuropathol | volume = 131 | issue = 6 | pages = 803-20 | month = Jun | year = 2016 | doi = 10.1007/s00401-016-1545-1 | PMID = 27157931 }}</ref> | |||
==Gross/radiologic== | ==Gross/radiologic== | ||
| Line 62: | Line 62: | ||
*Nonenhancing or enhancing. | *Nonenhancing or enhancing. | ||
*Occasionally well-circumscribed. | *Occasionally well-circumscribed. | ||
*Widespread dissemination in a gliomatosis cerebri fashion is very rare (DDx: Diffuse leptomeningeal glioneuronal tumour). | |||
Clinical symptoms: | Clinical symptoms: | ||
*Seizures. | *Seizures (2/3 of all cases). | ||
*Intracranial pressure. | *Intracranial pressure. | ||
*Focal neurologic decifits. | *Focal neurologic decifits. | ||
*Cognitive changes. | *Cognitive changes. | ||
*Incidental finding in 10%. | |||
==Microscopic== | ==Microscopic== | ||
| Line 86: | Line 88: | ||
*Some tumors may show a [[Polar Spongioblastoma|Spongioblastoma]]-like growth pattern. | *Some tumors may show a [[Polar Spongioblastoma|Spongioblastoma]]-like growth pattern. | ||
Anaplastic (grade | Anaplastic (grade 3) criteria:<ref>{{Cite journal | last1 = Giannini | first1 = C. | last2 = Scheithauer | first2 = BW. | last3 = Weaver | first3 = AL. | last4 = Burger | first4 = PC. | last5 = Kros | first5 = JM. | last6 = Mork | first6 = S. | last7 = Graeber | first7 = MB. | last8 = Bauserman | first8 = S. | last9 = Buckner | first9 = JC. | title = Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. | journal = J Neuropathol Exp Neurol | volume = 60 | issue = 3 | pages = 248-62 | month = Mar | year = 2001 | doi = | PMID = 11245209 }}</ref> | ||
*"Significant" or "brisk" mitotic activity. | *"Significant" or "brisk" mitotic activity. | ||
**That means for most neuropathologists >= 6 mitoses per 10 HPF. | **That means for most neuropathologists >= 6 mitoses per 10 HPF. | ||
*Microvacular proliferation. | *Microvacular proliferation. | ||
*Necrosis. | *Necrosis. | ||
*Rarely multnucleated cells. | |||
Note: | Note: | ||
* The clear cytoplasm around the nucleus is a fixation artefact and not seen in smear, frozen sections or rapid fixation. | |||
* Tumour cells may be plasmacytoid, i.e. have a [[plasma cell]]-like appearance.<ref name=pmid17284109>{{Cite journal | last1 = Aldape | first1 = K. | last2 = Burger | first2 = PC. | last3 = Perry | first3 = A. | title = Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. | journal = Arch Pathol Lab Med | volume = 131 | issue = 2 | pages = 242-51 | month = Feb | year = 2007 | doi = 10.1043/1543-2165(2007)131[242:CAOQLA]2.0.CO;2 | PMID = 17284109 | URL = http://www.archivesofpathology.org/doi/full/10.1043/1543-2165(2007)131%5B242:CAOQLA%5D2.0.CO;2 }}</ref> | * Tumour cells may be plasmacytoid, i.e. have a [[plasma cell]]-like appearance.<ref name=pmid17284109>{{Cite journal | last1 = Aldape | first1 = K. | last2 = Burger | first2 = PC. | last3 = Perry | first3 = A. | title = Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. | journal = Arch Pathol Lab Med | volume = 131 | issue = 2 | pages = 242-51 | month = Feb | year = 2007 | doi = 10.1043/1543-2165(2007)131[242:CAOQLA]2.0.CO;2 | PMID = 17284109 | URL = http://www.archivesofpathology.org/doi/full/10.1043/1543-2165(2007)131%5B242:CAOQLA%5D2.0.CO;2 }}</ref> | ||
**Also called minigemistocytes. | **Also called minigemistocytes. | ||
**The are usually strong GFAP+ve. | **The are usually strong GFAP+ve. | ||
*Few neural tumours have round nuclei - DDx in intraoperative specimen: | |||
*Few neural tumours have round nuclei - DDx: | |||
**Oligodendroglioma. | **Oligodendroglioma. | ||
**[[Lymphoma]]. | **[[Lymphoma]]. | ||
| Line 130: | Line 122: | ||
===Histologic grading=== | ===Histologic grading=== | ||
Come in two flavours: | Come in two flavours: | ||
# WHO grade | # WHO CNS grade 2 | ||
#*This is most oligodendrogliomas. | #*This is most oligodendrogliomas. | ||
#*Without genetic testing for [[IDH-1]]/2 and LOH 1p/19q, the tumor is called Oligodendroglioma, NOS. | #*Without genetic testing for [[IDH-1]]/2 and LOH 1p/19q, the tumor is called Oligodendroglioma, NOS. | ||
# WHO grade | # WHO CNS grade 3 | ||
#*Features for calling high grade:<ref name=Ref_PSNP98>{{Ref PSNP|98}}</ref> | #*Features for calling high grade:<ref name=Ref_PSNP98>{{Ref PSNP|98}}</ref> | ||
#**Endothelial hypertrophy. | #**Endothelial hypertrophy. | ||
#***Plump/large endothelial cells. | #***Plump/large endothelial cells. | ||
#**Necrosis. | #**Necrosis. | ||
#**High mitotic rate (6 mitoses/10 HPF | #**High mitotic rate (6 or more mitoses/10 HPF of 0.55mm²). | ||
#*Without genetic testing for [[IDH-1]]/2 and LOH 1p/19q, the tumor is called Anaplastic oligodendroglioma, NOS. | #*Without genetic testing for [[IDH-1]]/2 and LOH 1p/19q, the tumor is called Anaplastic oligodendroglioma, NOS. | ||
| Line 151: | Line 143: | ||
*ATRX +ve (nuclear retention). | *ATRX +ve (nuclear retention). | ||
**Useful for differentiating ''astrocytoma'' vs. ''oligodendroglioma''.<ref>{{Cite journal | last1 = Reuss | first1 = DE. | last2 = Sahm | first2 = F. | last3 = Schrimpf | first3 = D. | last4 = Wiestler | first4 = B. | last5 = Capper | first5 = D. | last6 = Koelsche | first6 = C. | last7 = Schweizer | first7 = L. | last8 = Korshunov | first8 = A. | last9 = Jones | first9 = DT. | title = ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. | journal = Acta Neuropathol | volume = 129 | issue = 1 | pages = 133-46 | month = Jan | year = 2015 | doi = 10.1007/s00401-014-1370-3 | PMID = 25427834 }}</ref> | **Useful for differentiating ''astrocytoma'' vs. ''oligodendroglioma''.<ref>{{Cite journal | last1 = Reuss | first1 = DE. | last2 = Sahm | first2 = F. | last3 = Schrimpf | first3 = D. | last4 = Wiestler | first4 = B. | last5 = Capper | first5 = D. | last6 = Koelsche | first6 = C. | last7 = Schweizer | first7 = L. | last8 = Korshunov | first8 = A. | last9 = Jones | first9 = DT. | title = ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. | journal = Acta Neuropathol | volume = 129 | issue = 1 | pages = 133-46 | month = Jan | year = 2015 | doi = 10.1007/s00401-014-1370-3 | PMID = 25427834 }}</ref> | ||
*H3K27me3 | *H3K27me3 -ve (nuclear loss).<ref>{{Cite journal | last1 = Filipski | first1 = K. | last2 = Braun | first2 = Y. | last3 = Zinke | first3 = J. | last4 = Roller | first4 = B. | last5 = Baumgarten | first5 = P. | last6 = Wagner | first6 = M. | last7 = Senft | first7 = C. | last8 = Zeiner | first8 = PS. | last9 = Ronellenfitsch | first9 = MW. | title = Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas. | journal = Acta Neuropathol | volume = | issue = | pages = | month = May | year = 2019 | doi = 10.1007/s00401-019-02025-9 | PMID = 31065834 }}</ref> | ||
*SOX10 +ve (up to 80%).<ref>{{Cite journal | last1 = Bannykh | first1 = SI. | last2 = Stolt | first2 = CC. | last3 = Kim | first3 = J. | last4 = Perry | first4 = A. | last5 = Wegner | first5 = M. | title = Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas. | journal = J Neurooncol | volume = 76 | issue = 2 | pages = 115-27 | month = Jan | year = 2006 | doi = 10.1007/s11060-005-5533-x | PMID = 16205963 }}</ref> | *SOX10 +ve (up to 80%).<ref>{{Cite journal | last1 = Bannykh | first1 = SI. | last2 = Stolt | first2 = CC. | last3 = Kim | first3 = J. | last4 = Perry | first4 = A. | last5 = Wegner | first5 = M. | title = Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas. | journal = J Neurooncol | volume = 76 | issue = 2 | pages = 115-27 | month = Jan | year = 2006 | doi = 10.1007/s11060-005-5533-x | PMID = 16205963 }}</ref> | ||
*Olig2 +ve. | |||
*H3 K27me3 nuclear loss in most cases. | |||
*NOGO-A often +ve. | |||
*p53 -ve or low expressed. | *p53 -ve or low expressed. | ||
*Ki-67 (usu. >5% in grade | *Ki-67 (usu. >5% in CNS grade 2). | ||
*May have neuronal "islands" (Synapto +ve, NeuN +ve). | *May have neuronal "islands" (Synapto +ve, NeuN +ve). | ||
==Molecular pathology== | ==Molecular pathology== | ||
Combined losses of 1p and 19q both and presence of IDH1 | Combined losses of 1p and 19q both and presence of IDH1 mutation in codon 132 or IDH2 mutation in codon 172 is required for final diagnosis and is prognostic and therapeutic relevant:<ref name=pmid18565359>{{cite journal |author=Fontaine D, Vandenbos F, Lebrun C, Paquis V, Frenay M |title=[Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice] |language=French |journal=Rev. Neurol. (Paris) |volume=164 |issue=6-7 |pages=595–604 |year=2008 |pmid=18565359 |doi=10.1016/j.neurol.2008.04.002 |url=}}</ref><ref>{{Cite journal | last1 = Wiestler | first1 = B. | last2 = Capper | first2 = D. | last3 = Hovestadt | first3 = V. | last4 = Sill | first4 = M. | last5 = Jones | first5 = DT. | last6 = Hartmann | first6 = C. | last7 = Felsberg | first7 = J. | last8 = Platten | first8 = M. | last9 = Feiden | first9 = W. | title = Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. | journal = Neuro Oncol | volume = 16 | issue = 12 | pages = 1630-8 | month = Dec | year = 2014 | doi = 10.1093/neuonc/nou138 | PMID = 25028501 }}</ref><ref>{{Cite journal | last1 = Cairncross | first1 = G. | last2 = Wang | first2 = M. | last3 = Shaw | first3 = E. | last4 = Jenkins | first4 = R. | last5 = Brachman | first5 = D. | last6 = Buckner | first6 = J. | last7 = Fink | first7 = K. | last8 = Souhami | first8 = L. | last9 = Laperriere | first9 = N. | title = Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. | journal = J Clin Oncol | volume = 31 | issue = 3 | pages = 337-43 | month = Jan | year = 2013 | doi = 10.1200/JCO.2012.43.2674 | PMID = 23071247 }}</ref> | ||
*Greater chemosensitivity | *Greater chemosensitivity to PCV regimen.<ref>{{Cite journal | last1 = Cairncross | first1 = G. | last2 = Wang | first2 = M. | last3 = Shaw | first3 = E. | last4 = Jenkins | first4 = R. | last5 = Brachman | first5 = D. | last6 = Buckner | first6 = J. | last7 = Fink | first7 = K. | last8 = Souhami | first8 = L. | last9 = Laperriere | first9 = N. | title = Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. | journal = J Clin Oncol | volume = 31 | issue = 3 | pages = 337-43 | month = Jan | year = 2013 | doi = 10.1200/JCO.2012.43.2674 | PMID = 23071247 }}</ref> | ||
*Better prognosis. | *Better prognosis compared to astrocytic tumors.<ref>{{Cite journal | last1 = Mur | first1 = P. | last2 = Mollejo | first2 = M. | last3 = Ruano | first3 = Y. | last4 = de Lope | first4 = ÁR. | last5 = Fiaño | first5 = C. | last6 = García | first6 = JF. | last7 = Castresana | first7 = JS. | last8 = Hernández-Laín | first8 = A. | last9 = Rey | first9 = JA. | title = Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors. | journal = Acta Neuropathol | volume = 126 | issue = 2 | pages = 277-89 | month = Aug | year = 2013 | doi = 10.1007/s00401-013-1130-9 | PMID = 23689617 }}</ref> | ||
*TERT promotor mutation present. | |||
*CDKN2A homozygoud deletion in <10% of grade 3 tumours. | |||
Note: If molecular testing fails, cases should be classified as Oligodendroglioma, NOS. | |||
DDx: | |||
*[[Neurocytoma]] also have perinuclear clearing and well-defined cellular borders. | |||
**Pineocytomatous/neurocytic rosettes = (irregular) rosette with a large meshwork of fibers (neuropil) at the centre. | |||
*Clear cell [[ependymoma]]. | |||
*[[Dysembryoplastic neuroepithelial tumour]]. | |||
*Oligodendroglial-like cells in [[Pilocytic astrocytoma]]. | |||
*Clear cell [[meningioma]]. (EMA +ve) | |||
*Clear cell renal carcinoma. (Pan-CK +ve) | |||
*Demyelinisation. | |||
* [[Astrocytoma]] | |||
** [[IDH-1]] mutant, but non-codeleted tumors with oligodendrogliom histologye are no longer classified as oligodendrogliomas on molecular basis. These tumors are classified as IDH-mutant astrocytoma. | |||
* Diffuse leptomeningeal glioneuronal tumour (1p/19q codeletion present, but IDH wildtype) | |||
Note: | Note: | ||
*Consider | *Consider Glioblastoma with oligo features when tumor is IDH1/2 wildtype and has no LOH 1p/19q and no ATRX loss. | ||
* | *Dual-genotype astrocytoma/oligodendroglioma are very rare. | ||
==See also== | ==See also== | ||